Aims to prevent, diagnose, and treat infectious diseases, with a strong focus on developing effective vaccines and improving immunity across populations. This theme addresses both emerging and persistent infections that impact children's health worldwide.
OAM BSc (Hons) GradDipClinEpi PhD
The Bacterial Respiratory Infectious Disease Group (BRIDG) has a major focus ear and lung disease involving Streptococcus pneumoniae and Haemophilus influenzae.
The Geospatial and Tuberculosis (GeoTB) team led by Kefyalew Alene focuses on designing an innovative approach for improving the efficiency and effectiveness of public health interventions to help control and ultimately eliminate tuberculosis in high-burden countries.
The Global Disease Modelling group informs development and implementation of drugs, medical treatments and non-medical interventions to effectively tackle disease. They build mathematical models of diseases, designed to take into account the complex constellation of interactions between pathogens, humans, diseases, the environment and entire healthcare systems.
Our aim is for all kids to have healthy skin. We work with communities to reduce the burden of Strep A skin sores and sore throats to prevent rheumatic fever.
The Infectious Disease Ecology and Modelling team led by Professor Nick Golding, combines mathematical and statistical modelling, ecology, and public health to address malaria and other infectious and vector-borne diseases. The team uses modelling and maps to measure the risk posed by some of the world’s most important and neglected diseases – including malaria, Japanese Encephalitis Virus and Covid-19 – and provide rapid modelling analyses to policy makers.
The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.
Our team’s vision is to reduce the burden of infectious diseases in children and their families through comprehensive approaches to understanding the burden of disease, developing and optimising diagnosis and treatment strategies and evaluating and informing current and future prevention programs.
The Strep A & ARF Therapeutics research team are working to accelerate research and clinical trials to improve penicillin formulation and treatment methods, to end RHD.
The Strep A Pathogenesis and Diagnostics team aims to understand key aspects of how Strep A causes different infections and diseases and use this information to develop improved ways to diagnose, treat and prevent these infections and diseases.
The Strep A Translation team aim to understand the epidemiology of Strep A infections in Australia and the world. Alongside this, they explore the implementation of endgame recommendations, health economics and new horizons.
The Strep A Vaccines research team is primarily focused on the Australian Strep A Vaccine Initiative (ASAVI) program of work funded by a $35 million grant from the Australian Government to accelerate the development of a Strep A vaccine (augmented by two multi-million-dollar philanthropic grants).
The mission of the Vaccine Trials Group is to improve the health of the community through immunisation and the prevention of infectious diseases.
